Home > News > News detail
DualityBio Announces 2026 Interim Results and Corporate Updates
DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform
DualityBio’s ADAM9 ADC DB-1317 Granted FDA Fast Track Designation for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
For more information, please
follow the official WeChat public
Scan the code to follow DualityBio official wechat
Phone：021-2601 8730
Address：Full floor, 11th floor, tower a, Datang International Plaza,China
Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area, Shanghai
